header
Image from OpenLibrary

Risk of hepatitis B reactivation in a cohort of Egyptian patients with chronic hepatitis C treated with direct- acting antiviral drugs (DAAs) / Reham Samir Abouserie Ahmed ; Supervised Mohammed Salah Abdelbary , Naglaa Ali Hassan Zayed , Saeed Moustafa Elnahhas

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Reham Samir Abouserie Ahmed , 2020Description: 157 , (10) P. : charts , facimiles , maps ; 25cmOther title:
  • خطر اعادة تنشيط الالتهاب الكبدى بى فى مجموعة من المرضى المصريين المصابين بالالتهاب الكبدى سى المزمن والذين يخضعون للعلاج بالادوية المباشرة المضادة لفيروس سى [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine Summary: Background: Concerns about hepatitis B virus reactivation (HBVr) were raised with introduction of direct-acting antivirals (DAA) for hepatitis C virus (HCV) treatment. aim: Assessment of the risk of HBVr in chronic HCV patients during or after DAA treatment. methods: A cohort of 166 chronic HCV Egyptian patients treated with SOF-based DAA regimens and positive for HBcAb total was evaluated; ten were HBsAg-positive, while 156 had past HBV exposure (HBsAg-negative/HBcAb-positive). Laboratory investigations including HBV- DNA, liver stiffness measurements (LSM) by Transient elastography and Acoustic Radiation Forced Impulse (ARFI) together with serum markers of fibrosis; aspartate-aminotransferase-to-platelet-ratio index (APRI) and (FIB-4) were done before and after 12 weeks of DAA therapy. HBVr was assessed on and after DAA therapy. results: All HCV patients achieved SVR12 and exhibited significant decline of serum transaminases, bilirubin, APRI, LSM and CAP measurements after HCV eradication. Compared to HCV patients with past HBV infection; current HCV/HBV co-infected patients had significantly higher baseline AST and AFP. Virological HBVr was diagnosed in two patients with HBsAg-positive by {u2265} 1 log10 IU/ml HBV-DNA levels, among whom one patient had clinical HBVr (>3 folds liver enzyme elevation) 12 weeks after DAA therapy, while none of HCV/past infected patients experienced HBVr.Patients with HBVr, had significantly higher baseline LSM compared to other patients. HCC was diagnosed in one cirrhotic HBsAg-positive patient after stoppage of DAA therapy. conclusion: HBVr was evident among HCV with current HBV co-infection following DAA therapy while past HBV infection does not seem to be a predisposing condition to HBVr
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.33.Ph.D.2020.Re.R (Browse shelf(Opens below)) Not for loan 01010110082188000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.33.Ph.D.2020.Re.R (Browse shelf(Opens below)) 82188.CD Not for loan 01020110082188000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Tropical Medicine

Background: Concerns about hepatitis B virus reactivation (HBVr) were raised with introduction of direct-acting antivirals (DAA) for hepatitis C virus (HCV) treatment. aim: Assessment of the risk of HBVr in chronic HCV patients during or after DAA treatment. methods: A cohort of 166 chronic HCV Egyptian patients treated with SOF-based DAA regimens and positive for HBcAb total was evaluated; ten were HBsAg-positive, while 156 had past HBV exposure (HBsAg-negative/HBcAb-positive). Laboratory investigations including HBV- DNA, liver stiffness measurements (LSM) by Transient elastography and Acoustic Radiation Forced Impulse (ARFI) together with serum markers of fibrosis; aspartate-aminotransferase-to-platelet-ratio index (APRI) and (FIB-4) were done before and after 12 weeks of DAA therapy. HBVr was assessed on and after DAA therapy. results: All HCV patients achieved SVR12 and exhibited significant decline of serum transaminases, bilirubin, APRI, LSM and CAP measurements after HCV eradication. Compared to HCV patients with past HBV infection; current HCV/HBV co-infected patients had significantly higher baseline AST and AFP. Virological HBVr was diagnosed in two patients with HBsAg-positive by {u2265} 1 log10 IU/ml HBV-DNA levels, among whom one patient had clinical HBVr (>3 folds liver enzyme elevation) 12 weeks after DAA therapy, while none of HCV/past infected patients experienced HBVr.Patients with HBVr, had significantly higher baseline LSM compared to other patients. HCC was diagnosed in one cirrhotic HBsAg-positive patient after stoppage of DAA therapy. conclusion: HBVr was evident among HCV with current HBV co-infection following DAA therapy while past HBV infection does not seem to be a predisposing condition to HBVr

Issued also as CD

There are no comments on this title.

to post a comment.